Loading
Olema Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Jan 2025.
Olema Pharmaceuticals, Inc.: what insiders have been doing
Olema Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 10 insiders have disclosed 18 filings since 18 October 2025.
Only sales appear on the open market, 8 sales in all totalling €1.0M, filed by 3 insiders. Biggest ticket of the year: €244k, sold by Myles David C. and made public on 14 January 2026.
Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 18 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 10 purchases and 40 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -162.5 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
101
Thresholds
n/a
Buy Volume
€18M
10 ops. · all time
Sell Volume
€50M
40 ops. · all time
Who traded when
BuySaleCyrus Harmon6 sales
David C. Myles2 sales
G. Walmsley Graham2 sales
Bain Capital Life Sciences Investors, LLC1 buy
Shane William Charles Kovacs1 sale
Since the insiders bought
- +459.7%Entry US$5.14 · Close at T+365 US$28.77
- +144.7%Entry US$3.71 · Close at T+365 US$9.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.80
Analyst consensus
10 analysts1.33/5
US$16.00Target US$36.50(+437%)US$59.00
Income statement
EBITDA-US$178.2M
Net income-US$162.5M0.0% margin
Valuation
PER (forward)-2.6x
P/Book1.4x
Beta2.01
Balance sheet & cash
Market capUS$595M
Total debtUS$4.2M
Free Cash Flow-US$146.7M
Debt / Equity1%
Profitability & ownership
ROE-52.7%
ROA-31.8%
% insiders1.8%
% institutions119.6%
Last declaration on 27 July 2026
Declarations101 total
12,500 shares@ US$11.5790.018% mcap2.6% of flowCommon StockSEC:0001831410-26-000008:0
12,500 shares@ US$11.7140.018% mcap2.6% of flowCommon StockSEC:0001831410-26-000008:1
12,500 shares@ US$11.71360.018% mcap2.6% of flowCommonSEC144:0001959173-26-005357
12,500 shares@ US$11.5790.018% mcap2.6% of flowCommonSEC144:0001959173-26-005343
15,000 shares@ US$4.37100.0% of flowCommon StockSEC:0001749432-26-000004:0
11,700 shares0Common StockSEC:0002110895-26-000005:0
10,000 shares@ US$26.884.7% of flowCommon StockSEC:0001831410-26-000004:0
3,489 shares@ US$29.121.8% of flowCommon StockSEC:0001831410-26-000002:0
3,822 shares@ US$28.0114.3% of flowCommon StockSEC:0001579397-26-000002:0
10,000 shares@ US$28.3434.9% of flowCommon StockSEC:0001831216-26-000003:0
8,500 shares0Common StockSEC:0001831218-25-000004:0
2,881 shares@ US$28.531.4% of flowCommon StockSEC:0001831410-25-000007:0
40,000 shares@ US$15.2556.4% of flowCommon StockSEC:0001905871-25-000004:0
1,225 shares@ US$28.084.2% of flowCommon StockSEC:0001831216-25-000004:0
209,690 shares@ US$4.406100.0% of flowCommon StockSEC:0001336504-25-000009:0
75,000 shares0Common StockSEC:0001579397-25-000007:0
225,000 shares0Common StockSEC:0001579397-25-000005:0
35,868 shares@ US$0.39100.0% of flowCommon StockSEC:0001162157-25-000005:0
10,000 shares@ US$8.041.4% of flowCommon StockSEC:0001831410-25-000004:0
235,450 sharesCommon stock, $0.0001 par valueSEC:0000921895-25-000106:0
161,810 sharesCommon stock, $0.0001 par valueSEC:0000921895-25-000106:1
22,740 sharesCommon stock, $0.0001 par valueSEC:0000921895-25-000106:2
300,000 shares@ US$5.7579100.0% of flowCommon StockSEC:0000950170-25-004870:0
Canonical exit: 8 Apr 2025 (T+90)
700,761 shares@ US$6.7519.5% of flowCommon StockSEC:0000935836-24-000764:0
700,761 shares@ US$6.7519.4% of flowCommon StockSEC:0000935836-24-000763:0
25 of 101 declarations
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. (ticker: OLMA) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States. For French-speaking investors, Olema is best understood as a clinical-stage oncology story: the company does not yet rely on broad commercial product sales, and its valuation is primarily driven by clinical execution, scientific differentiation, pipeline optionality, and eventual regulatory and partnership outcomes. Founded in 2006 under the original name CombiThera, Inc., Olema is headquartered in San Francisco, California, and also maintains operations in Cambridge, Massachusetts.
Olema’s business focus is highly specialized. The company is centered on oncology, with a particular emphasis on metastatic breast cancer and, more broadly, endocrine-driven cancers. Its research and development strategy leverages a deep understanding of nuclear receptors, hormone-dependent tumor biology, and mechanisms of acquired resistance. The company’s lead asset is palazestrant, a next-generation endocrine therapy being advanced across multiple settings, including combination regimens and monotherapy. Olema is running two important Phase 3 studies, OPERA-01 and OPERA-02, which makes the company a significant clinical-stage participant in the breast-cancer treatment landscape. In parallel, Olema is also developing OP-3136, a KAT6 inhibitor in early-stage clinical development, which broadens the pipeline beyond a single asset and potentially beyond a single indication.
Read moreShow less
From a competitive standpoint, Olema operates in a crowded and scientifically demanding segment of the biopharmaceutical industry. It competes against larger pharmaceutical companies and specialized oncology biotechs focused on HR+/HER2- breast cancer and related endocrine pathways. Olema’s key differentiation lies in its focused scientific platform, its pipeline depth, and its strategy of pairing proprietary assets with standard-of-care agents to improve outcomes. A notable example of this approach is the clinical collaboration with Novartis for the OPERA-02 study, where ribociclib supply supports the combination trial design. That partnership underscores Olema’s ability to work with established oncology players to accelerate data generation and potentially strengthen future commercialization pathways.
Recent milestones have been material. In 2026, Olema reported ongoing execution across OPERA-01 and OPERA-02 and indicated first clinical data for OP-3136 would be presented at ASCO. The company also executed a public equity offering in 2025, improving its financial runway for clinical development. For investors monitoring SEC Form 4 insider transactions, Olema is also a name where insider activity can attract attention because it may signal management confidence, equity-based compensation activity, or portfolio adjustments. Overall, Olema Pharmaceuticals remains a higher-risk, high-upside U.S. biotech name whose medium-term investment case depends on clinical success, regulatory progress, and the strength of strategic partnerships.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
